JNJ 28871063 hydrochloride

Pricing Availability   Qty
说明: Potent ErbB receptor family inhibitor
化学名: 5E-4-Amino-6-(4-benzyloxy-3-chlorophenylamino)pyrimidine-5-carboxaldehyde N-(2-morpholin-4-ylethyl) oxime hydrochloride
纯度: ≥97% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for JNJ 28871063 hydrochloride

JNJ 28871063 hydrochloride is a potent and selective ErbB receptor family inhibitor (IC50 values are 21, 22 and 38 nM for ErbB4, EGFR and ErbB2 respectively). Displays potent growth inhibition of human cancer cell lines overexpressing ErbB2 in vitro (IC50 = 60 - 168 nM) and inhibits growth of human tumor xenografts in vivo. Brain penetrant and orally active.

化合物库 for JNJ 28871063 hydrochloride

JNJ 28871063 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for JNJ 28871063 hydrochloride

分子量 519.42
公式 C24H27ClN6O3.HCl
储存 Desiccate at +4°C
纯度 ≥97% (HPLC)
CAS Number 944342-90-9
PubChem ID 17747413
InChI Key ZXKZRKQMKNRZNN-GZPZNDDGSA-N
Smiles NC1=C(/C=N/OCCN2CCOCC2)C(NC3=CC(Cl)=C(OCC4=CC=CC=C4)C=C3)=NC=N1.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for JNJ 28871063 hydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 25.97 50

制备储备液 for JNJ 28871063 hydrochloride

以下数据基于产品分子量 519.42。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.5 mM 3.85 mL 19.25 mL 38.5 mL
2.5 mM 0.77 mL 3.85 mL 7.7 mL
5 mM 0.39 mL 1.93 mL 3.85 mL
25 mM 0.08 mL 0.39 mL 0.77 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for JNJ 28871063 hydrochloride

分析证书/产品说明书
选择另一批次:

参考文献 for JNJ 28871063 hydrochloride

参考文献是支持产品生物活性的出版物。

Contessa and Hamstra (2008) Revoking the privilege: targeting HER2 in the central nervous system. Mol.Pharmacol. 73 271 PMID: 17981994

Emanuel et al (2008) Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol.Pharmacol. 73 338 PMID: 17975007

Guessous et al (2008) Signaling pathways in medulloblastoma. J.Cell.Phys. 217 577 PMID: 18651559


If you know of a relevant reference for JNJ 28871063 hydrochloride, please let us know.

按产品操作查看相关产品

查看全部 EGFR Inhibitors

关键词: JNJ 28871063 hydrochloride, JNJ 28871063 hydrochloride supplier, Potent, ErbB, receptor, family, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, JNJ28871063, hydrochloride, 3352, Tocris Bioscience

篇 JNJ 28871063 hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 JNJ 28871063 hydrochloride 的引用文献。 您是否知道使用了 Tocris JNJ 28871063 hydrochloride 的优秀论文? 请告知我们.

JNJ 28871063 hydrochloride 的评论

目前没有该产品的评论。 Be the first to review JNJ 28871063 hydrochloride and earn rewards!

Have you used JNJ 28871063 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.